Endogenous and exogenous histamine influences on angiogenesis related gene expression of mice mammary adenocarcinoma

Inflammation Research

Volumn 56, Issue SUPPL. 1, 2007, Pages

  Hegyesi, H ^a   Toth S ^a   Molnar V ^a   Fulop K A ^a   Falus, A ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE; INTERLEUKIN 2; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; BREAST ADENOCARCINOMA; CANCER CELL; CONFERENCE PAPER; CONTROLLED STUDY; GENE EXPRESSION; IN VIVO STUDY; METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADENOCARCINOMA; ANIMALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTAMINE; HISTIDINE DECARBOXYLASE; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC;

EID: 34548359213     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-006-0518-6     Document Type: Conference Paper

References (8)

1. Pos Z, Safrany G, Muller K, Toth S, Falus A, Hegyesi H. Phenotypic profi ling of engineered mouse melanomas with manipulated histamine production identifi es histamine H2 receptor and rho-C as histamine-regulated melanoma progression markers. Cancer Res 2005; 65(10): 4458-66.
2. Johansson M, Henriksson R, Bergenheim AT, Koskinen LD. Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma. Br J Cancer 2000; 83: 826-32.
3. Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J Immunol 1994; 153: 4940-7.
4. Applied Biosystems, User bulletin no. 2. Relative quantifi cation of gene expression; 1997. (http://docs.appliedbiosystems.com/searchdodnum. taf?dodnum=4303859)
5. Ohtsu H, Tanaka S, Terui T et al.: Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett 2001; 502(1-2): 53-6.
6. Iwasaka C, Tanaka K, Abe M, Sato Y: Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol 1996; 169: 522-31.
7. Heroult M, Schaffner F, Augustin HG. Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exptl Cell Res 2006; 312: 642-50.
8. Haluska P, Adjei AA. Receptor tyrosine kinase inhibitors. Curr Opin Investig Drugs 2001; 2(2): 280-6.